Clinical Trial Search

Primary: Assess the Safety and Tolerability of Defactinib (VS-6063) in Japanese Subjects With Non-hematologic Malignancies — 3; 3; 3; 3 participants

Primary: Change From Baseline in Modified Total Sharp Score (mTSS) at Week 52 — 1.58; 0.36 units on a scale — p=<0.001

Primary: Change From Baseline to Week 8 in the Children's Depression Rating Scale, Revised (CDRS-R) Total Score — -23.07; -24.79; -22.61 Score on a Scale — p=0.226

Primary: Overall Objective Response — 5; 22; 8 participants

Primary: Physician Global Assessment Using Physician Overall Opinion Question of Patient and Observer Scar Assessment Scale (POSAS) — 4.00; 4.68; 4.61; 4.86 units on scale…

Primary: Percentage of Participants With Hepatitis B e-Antigen (HBeAg) Seroconversion at 100 Weeks After Start of Treatment — 27.4; 29.5; 36.3 percentage of participants — p=0.6853

Primary: Rate of Major and Minor Hypoglycaemic Episodes — 0; 0; 13.63; 21.83 Episodes /year of patient exposure

Primary: IwCLL-WG Defined Complete Response (CR) — 1 participants

Primary: Change in Western Ontario and McMaster Universities Arthritis Index (WOMAC) — 3.0; 2.9; 8.0; 7.4 units on a scale

Primary: Change in Glycosylated Haemoglobin (HbA1c) — -1.28; -1.30 percentage of glycosylated haemoglobin

Primary: Main Trial (Primary Endpoint): Change in Glycosylated Haemoglobin (HbA1c) After 26 Weeks of Treatment — -0.73; -0.68 percentage of glycosylated haemoglobin

Primary: Main Trial (Primary Endpoint): Change in Glycosylated Haemoglobin (HbA1c) After 26 Weeks of Treatment — -1.65; -1.72 percentage of glycosylated haemoglobin

Primary: Rate of Achieving the Target on Blood Intact Parathyroid Hormone Level According to Kidney Development Improvement Global Outcome (KDIGO) Guidelines. — 30.8; 57.1; 90.0…

Primary: Change in HbA1c (Glycosylated Haemoglobin) After 26 Weeks of Treatment — -1.38; -1.42 percentage of glycosylated haemoglobin

Primary: Determine Response Rate of Patients > or = to 65 Yrs Diagnosed — 63; 24 participants